CRISPR 및 Cas 유전자 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

CRISPR And Cas Genes Market Growth & Trends:

The global CRISPR and Cas genes market size is expected to reach USD 11.33 billion by 2030, growing at a CAGR of 16.12% from 2025 to 2030, according to a new report by Grand View Research, Inc. The use of CRISPR-Cas systems in diagnostics and the assessment of evolutionary analysis in prokaryotes has significantly increased, owing to the developments in the field of genome editing. The application of this technology enables easy and cost-efficient editing of genes. Genome editing has made a significant advancement in biomedical research, with the present trend of cutting-edge techniques paving the way for the future treatment of different genetic and non-genetic disorders.

The development and implementation of more effective ways for gene targeting and the generation of gene-edited avian species have been facilitated by the availability of the CRISPR/Cas9-mediated gene and genome editing technology. According to an article published on Frontiers in February 2021, CRISPR/Cas9 has become a robust and important tool for gene editing in the poultry industry. Potential applications in several fields would further boost the demand for this technology. The COVID-19 outbreak shifted the researcher's emphasis to the development of COVID-19 molecular diagnostic tools based on this technology. For instance, in March 2021, Nanyang Technological University researchers in Singapore created a COVID-19 test based on CRISPR that provides results in 30 minutes.

Even after the virus has mutated, this test still discovers it. This would further encourage the other key players to leverage this technique, thereby driving the industry's growth. This technology is increasingly being used for several medical and other applications. Competition over patents for such a gene-editing technology is expected to grow, as more academic institutions and biotech companies attempt to develop new commercial applications of this technology. In addition, there is a lot of potential for this technique to advance with the use of machine learning technologies. For instance, in August 2022, Synthego launched engineered cell libraries, a cutting-edge service that expands access to CRISPR by giving arrayed CRISPR-edited cells for use directly in functional screening experiments.

It has potential applications in disease research. Key players offer tools and solutions for each step of the gene editing workflow. Integrating several tools, services, and improved processes makes it possible to complete research experiments rapidly and with little effort. Moreover, key players have raised significant funding to support the R&D of the CRISPR & Cas9 gene-editing approach. For instance, in April 2021, Vertex Pharmaceuticals collaborated with CRISPR Therapeutics to develop and manufacture a new CRISPR/Cas9-based gene editing therapy called CTX001, a potential therapeutic option for transfusion-dependent beta-thalassemia and Sickle Cell Disease (SCD). In January 2020, Mammoth Biosciences raised USD 45 million to develop next-gen CRISPR products for therapeutics & diagnostics purposes. This would further be used to develop the company's CRISPR genes-driven diagnostics portfolio.

CRISPR And Cas Genes Market Report Highlights:

• By product and services, the product segment dominated the industry in 2024 and accounted for the highest share of 77.39%
• The biomedical segment dominated the industry in 2024. Extensive research and a significant rise in the number of research studies utilizing the advanced technique for genome editing have contributed to the segment growth
• The biotechnology and pharmaceutical companies dominated the market in 2024, accounting for 49.56% of overall revenue share. Key players are adopting this technology to produce biological models for human diseases and further accelerate new therapeutic target identification
• North America dominated the market and accounted for the highest revenue share of 41.36% in 2024 owing to the presence of several pharmaceutical giants, increased research funding, a high number of research approvals, and the need for novel therapeutics

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information Analysis
  • 1.3.1. Market Formulation & Data Visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Need For Novel Therapeutics
    • 3.2.1.2. Rising Demand For Gene Editing
    • 3.2.1.3. Rising Incidence Of Cancer
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Off-Target Effects Of CRISPR Technology
    • 3.2.2.2. High Cost Factor, Intellectual Property Disputes & Ethical Dilemma
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product & Service Business Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global CRISPR And CAS Genes Market: Product & Service Movement Analysis
• 4.3. Global CRISPR And CAS Genes Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Products
  • 4.4.1. Products Market, 2018 - 2030 (USD Million)
  • 4.4.2. Kits & Reagents
    • 4.4.2.1. Kits & Reagents Market, 2018 - 2030 (USD Million)
    • 4.4.2.2. Cas Proteins & Enzymes
      • 4.4.2.2.1. Cas Proteins & Enzymes Market, 2018 - 2030 (USD Million)
    • 4.4.2.3. Guide RNA
      • 4.4.2.3.1. Guide RNA Market, 2018 - 2030 (USD Million)
    • 4.4.2.4. Others
      • 4.4.2.4.1. Others Market, 2018 - 2030 (USD Million)
  • 4.4.3. Libraries
    • 4.4.3.1. Libraries Market, 2018 - 2030 (USD Million)
  • 4.4.4. Design Tool
    • 4.4.4.1. Design Tool Market, 2018 - 2030 (USD Million)
  • 4.4.5. Antibodies
    • 4.4.5.1. Antibodies Market, 2018 - 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Other Products Market, 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Services Market, 2018 - 2030 (USD Million)
  • 4.5.2. Cell Line Engineering
    • 4.5.2.1. Cell Line Engineering Market, 2018 - 2030 (USD Million)
  • 4.5.3. gRNA Design & Synthesis
    • 4.5.3.1. gRNA Design & Synthesis Market, 2018 - 2030 (USD Million)
  • 4.5.4. Screening Services
    • 4.5.4.1. Screening Services Market, 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global CRISPR And CAS Genes Market: Application Movement Analysis
• 5.3. Global CRISPR And CAS Genes Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Biomedical
  • 5.4.1. Biomedical Market, 2018 - 2030 (USD Million)
  • 5.4.2. Genome Engineering
    • 5.4.2.1. Genome Engineering Market, 2018 - 2030 (USD Million)
  • 5.4.3. Disease Model Studies
    • 5.4.3.1. Disease Model Studies Market, 2018 - 2030 (USD Million)
  • 5.4.4. Functional Genomics
    • 5.4.4.1. Functional Genomics Market, 2018 - 2030 (USD Million)
  • 5.4.5. Epigenetics
    • 5.4.5.1. Epigenetics Market, 2018 - 2030 (USD Million)
  • 5.4.6. Others
    • 5.4.6.1. Other Biomedical Applications Market, 2018 - 2030 (USD Million)
• 5.5. Agricultural
  • 5.5.1. Agricultural Market, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. Global CRISPR And CAS Genes Market: End Use Movement Analysis
• 6.3. Global CRISPR And CAS Genes Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Biotechnology & Pharmaceutical Companies
  • 6.4.1. Biotechnology & Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
• 6.5. Academic & Government Research Institutes
  • 6.5.1. Academic & Government Research Institutes Market, 2018 - 2030 (USD Million)
• 6.6. Contract Research Organizations (CROs)
  • 6.6.1. Contract Research Organizations (CROs) Market, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. CRISPR And CAS Genes Market, 2018 - 2030 (USD MILLION)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Germany CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.4.3. UK
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. UK CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. South Korea CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Australia CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Thailand CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait CRISPR And CAS Genes Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.1.3. Product/Service Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Illumina
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.2.3. Product/Service Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Agilent Technologies
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.3.3. Product/Service Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Synthego
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.4.3. Product/Service Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Danaher
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.5.3. Product/Service Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Origene Technologies
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.6.3. Product/Service Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. GenScript
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.7.3. Product/Service Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Lonza
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.8.3. Product/Service Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Revvity, Inc.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.9.3. Product/Service Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Merck KGaA
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.10.3. Product/Service Benchmarking
    • 8.4.10.4. Strategic Initiatives